Rodman & Renshaw Reiterates Neutral Rating for Viracta Therapeutics (NASDAQ:VIRX)

Viracta Therapeutics (NASDAQ:VIRX)‘s stock had its “neutral” rating restated by stock analysts at Rodman & Renshaw in a note issued to investors on Friday,Benzinga reports. They currently have a $0.25 price target on the stock, down from their prior price target of $3.50. Rodman & Renshaw’s price target would suggest a potential upside of 56.25% from the company’s current price.

Separately, Royal Bank of Canada decreased their price target on Viracta Therapeutics from $4.00 to $2.00 and set an “outperform” rating on the stock in a research note on Thursday, November 14th. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $4.05.

Viracta Therapeutics Stock Performance

Viracta Therapeutics stock opened at $0.16 on Friday. The company has a market capitalization of $6.36 million, a price-to-earnings ratio of -0.15 and a beta of 0.67. The company’s 50 day simple moving average is $0.19 and its 200-day simple moving average is $0.31. Viracta Therapeutics has a 1 year low of $0.13 and a 1 year high of $1.31.

Hedge Funds Weigh In On Viracta Therapeutics

An institutional investor recently bought a new position in Viracta Therapeutics stock. Stonepine Capital Management LLC acquired a new position in shares of Viracta Therapeutics, Inc. (NASDAQ:VIRX) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 500,000 shares of the company’s stock, valued at approximately $116,000. Stonepine Capital Management LLC owned approximately 1.27% of Viracta Therapeutics as of its most recent filing with the Securities & Exchange Commission. Institutional investors own 31.37% of the company’s stock.

Viracta Therapeutics Company Profile

Viracta Therapeutics, Inc, a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir.